Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANTX - AN2 Therapeutics, Inc.

IEX Last Trade
1.39
-0.005   -0.360%

Share volume: 1,459
Last Updated: Thu 26 Dec 2024 08:16:41 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 1.30%

PREVIOUS CLOSE
CHG
CHG%
$1.40
-0.01
-0.36%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-2.86%
1 Month
-2.16%
3 Months
28.91%
6 Months
-35.55%
1 Year
-93.47%
2 Year
-85.30%
Key data
Stock price
$1.39
P/E Ratio 
0.00
DAY RANGE
$1.36 - $1.40
EPS 
$0.00
52 WEEK RANGE
$1.03 - $22.22
52 WEEK CHANGE
-$93.49
MARKET CAP 
33.722 M
YIELD 
N/A
SHARES OUTSTANDING 
29.842 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$222,315
AVERAGE 30 VOLUME 
$332,063
Company detail
CEO: Eric Easom
Region: US
Website: an2therapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Recent news